These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 27278268)

  • 21. Recent advances in the understanding of mastocytosis: the role of KIT mutations.
    Orfao A; Garcia-Montero AC; Sanchez L; Escribano L;
    Br J Haematol; 2007 Jul; 138(1):12-30. PubMed ID: 17555444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Class III receptor tyrosine kinases: role in leukaemogenesis.
    Reilly JT
    Br J Haematol; 2002 Mar; 116(4):744-57. PubMed ID: 11886377
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparative aspects of mast cell neoplasia in animals and the role of KIT in prognosis and treatment.
    Tamlin VS; Bottema CDK; Peaston AE
    Vet Med Sci; 2020 Feb; 6(1):3-18. PubMed ID: 31650704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cutaneous and splenic mastocytosis in a juvenile Malayan tiger.
    Smedley RC; Stedman NL; Kiupel M
    J Vet Diagn Invest; 2022 Mar; 34(2):288-291. PubMed ID: 35075959
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Therapeutically relevant mutations in the receptor tyrosine kinase KIT in mastocytosis].
    Sotlar K
    Verh Dtsch Ges Pathol; 2007; 91():169-76. PubMed ID: 18314612
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aberrant autophosphorylation of c-Kit receptor in canine mast cell tumor cell lines.
    Takeuchi Y; Fujino Y; Watanabe M; Nakagawa T; Ohno K; Sasaki N; Sugano S; Tsujimoto H
    Vet Immunol Immunopathol; 2010 Oct; 137(3-4):208-16. PubMed ID: 20591500
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of c-KIT exon 11 mutations in canine gastrointestinal stromal tumours.
    Takanosu M; Amano S; Kagawa Y
    Vet J; 2016 Jan; 207():118-123. PubMed ID: 26631948
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heterogeneity of internal tandem duplications in the c-kit of dogs with multiple mast cell tumours.
    Amagai Y; Tanaka A; Matsuda A; Jung K; Oida K; Nishikawa S; Jang H; Matsuda H
    J Small Anim Pract; 2013 Jul; 54(7):377-80. PubMed ID: 23614673
    [TBL] [Abstract][Full Text] [Related]  

  • 29. C-kit mutations and mast cell disorders. A model of activating mutations of growth factor receptors.
    Pignon JM
    Hematol Cell Ther; 1997 Apr; 39(2):114-6. PubMed ID: 9168310
    [TBL] [Abstract][Full Text] [Related]  

  • 30. KIT and mastocytosis.
    Lim KH; Pardanani A; Tefferi A
    Acta Haematol; 2008; 119(4):194-8. PubMed ID: 18566536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of paediatric mastocytosis with a polymorphism resulting in an amino acid substitution (M541L) in the transmembrane domain of c-KIT.
    Foster R; Byrnes E; Meldrum C; Griffith R; Ross G; Upjohn E; Braue A; Scott R; Varigos G; Ferrao P; Ashman LK
    Br J Dermatol; 2008 Nov; 159(5):1160-9. PubMed ID: 18795925
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The diagnostic and predictive role of kit (CD117)].
    Dirnhofer S; Zimpfer A; Went P
    Ther Umsch; 2006 Apr; 63(4):273-8. PubMed ID: 16689459
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of a secondary mutation in the KIT kinase domain correlated with imatinib-resistance in a canine mast cell tumor.
    Nakano Y; Kobayashi M; Bonkobara M; Takanosu M
    Vet Immunol Immunopathol; 2017 Jun; 188():84-88. PubMed ID: 28615132
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting c-kit in the therapy of mast cell disorders: current update.
    El-Agamy DS
    Eur J Pharmacol; 2012 Sep; 690(1-3):1-3. PubMed ID: 22789565
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity.
    Debiec-Rychter M; Wasag B; Stul M; De Wever I; Van Oosterom A; Hagemeijer A; Sciot R
    J Pathol; 2004 Apr; 202(4):430-8. PubMed ID: 15095270
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dysregulation of tyrosine kinases and use of imatinib in small animal practice.
    Bonkobara M
    Vet J; 2015 Aug; 205(2):180-8. PubMed ID: 25592261
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation of KIT modulates the function of tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) in mast cells.
    Förster A; Grotha SP; Seeger JM; Rabenhorst A; Gehring M; Raap U; Létard S; Dubreuil P; Kashkar H; Walczak H; Roers A; Hartmann K
    Allergy; 2015 Jul; 70(7):764-74. PubMed ID: 25833810
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of KIT activating mutations in paediatric solitary mastocytoma.
    Ma D; Stence AA; Bossler AB; Hackman JR; Bellizzi AM
    Histopathology; 2014 Jan; 64(2):218-25. PubMed ID: 24128084
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytological, immunohistochemical and mutational analysis of a gastric gastrointestinal stromal tumour in a cat.
    Morini M; Gentilini F; Pietra M; Spadari A; Turba ME; Mandrioli L; Bettini G
    J Comp Pathol; 2011; 145(2-3):152-7. PubMed ID: 21333305
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic significance of DOG-1 and PKC-θ expression and c-Kit/PDGFRA mutations in gastrointestinal stromal tumours.
    Wang C; Jin MS; Zou YB; Gao JN; Li XB; Peng F; Wang HY; Wu ZD; Wang YP; Duan XM
    Scand J Gastroenterol; 2013 Sep; 48(9):1055-65. PubMed ID: 23862765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.